For US Healthcare Professionals Important Safety Information Full Prescribing Information

Efficacy of CroFab

CroFab Is Clinically Proven to Arrest Local Injury, Resolve Systemic Effects, and Reduce Hematologic Effects of Envenomation1

Clinically Proven to Achieve Initial and Clinically Relevant Control of North American Pit Viper Envenomation1

Graph showing 98% of patients achieved initial control of envenomation and 95% experienced a clinical response with CroFab

Based on 2 open-label trials with 42 patients with mild or moderate envenomation. Exclusion criteria for both trials included envenomation by copperhead snakes. In study 1, patients were given up to 2 doses of 4 vials each to gain initial control. In study 2, patients were given up to 2 doses of 6 vials each to gain initial control.1

Level 1 Evidence Specifically for Copperhead Envenomation3

CroFab Administration Resulted in Improved Limb Function Following Copperhead Envenomation3

Graph showing improvement in limb function over 28 days with CroFab compared with placebo

Source: Gerardo CJ et al. Ann Emerg Med. 2017;70(2):233-244.e3.

Clinically meaningful and statistically significant improvements in limb function at 7, 10, and 14 days following envenomation compared with placebo (P<0.05) for all 3 time points).3,4

PSFS, Patient-Specific Functional Scale.
Based on a double-blind, placebo-controlled trial with 74 patients with mild or moderate envenomation.
Patients with severe envenomation were excluded. Patients were given up to 2 doses of 6 vials each to gain initial control.3

Watch Dr. Rutherfoord Rose discuss using
CroFab to treat copperhead envenomation.


CroFab Clinical Studies

Review publications evaluating efficacy and safety for CroFab

View Articles
CroFab safety profile clipboard icon

CroFab safety is backed by more than 20 years of clinical experience1

View Safety Profile
CroFob dosing vial icon

Appropriate dosing achieves initial and sustained control of envenomation1

Learn How to Dose CroFab
CroFab patient experience icon

Real-world use supports improved outcomes with CroFab1

Hear Real Patient Experiences

1. CroFab®. Prescribing information. BTG International Inc.; August 2018. 2. WHO Expert Committee on Biological Standardization. WHO Technical Report Series, No. 1004, Annex 5; 2017. Accessed September 13, 2023. 3. Data on file. BTG International Inc. 4. Tasoulis T, Isbister GK. Toxins (Basel). 2017;9(9):290. 5. Gutiérrez JM et al. [Erratum in: Nat Rev Dis Primers. 2017;3:17079]. Nat Rev Dis Primers. 2017;3:17063. 6. Strickland JL et al. Sci Rep. 2018;8(1):17622. 7Riley BD et al. In: Nelson LS et al, eds. Goldfrank’s Toxicologic Emergencies. 9th ed. McGraw-Hill Professional; 2010. 8Borja M et al. Toxins (Basel). 2018;10(1):35.